Showing results (141-150 of 190) with videos related to
Sort By:
Pageof 19
British Journal of Cancer|November 23, 2016
Trastuzumab-associated cardiac events in the Persephone trialHelena M Earl, Anne-Laure Vallier, Janet Dunn, et al.Breast Cancer Research and Treatment|November 23, 2017
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trialJoyce O'Shaughnessy, Katarina Petrakova, Gabe S Sonke, et al.European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomyMarjanka K Schmidt, Jennifer E Kelly, Anne Brédart, et al.Breast Cancer Research and Treatment|May 8, 2012
Expression of activated type I receptor tyrosine kinases in early breast cancerMelanie Spears, Hans Christian Pederson, Nicola Lyttle, et al.BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7Aleix Prat, Nadia Solovieff, Fabrice André, et al.Breast Cancer Research and Treatment|June 19, 2010
Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group studyJanine L Mansi, Ann Yellowlees, Julian Lipscombe, et al.Breast Cancer Research and Treatment|March 11, 2011
The p160 ER co-regulators predict outcome in ER negative breast cancerMelanie Spears, Steffi Oesterreich, Ilenia Migliaccio, et al.The Lancet. Oncology|January 17, 2018
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyEllen R Copson, Tom C Maishman, Will J Tapper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group studyT R Jeffry Evans, Ann Yellowlees, Elizabeth Foster, et al.Pageof 19